Brachytherapy efficacy and safety in the treatment of primitive tongue carcinomas: experience from the Oscar Lambret Center
Journal of Stomatology Oral and Maxillofacial Surgery · 2025
DOI: 10.1016/j.jormas.2025.102416 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Stomatology Oral and Maxillofacial Surgery, 2025. Verfasst von Aziliz Dreszer und 5 weiteren Autor:innen. Beteiligte Einrichtung: Univ. Lille, CHU Lille, Department of Odontology, Lille, France. Electronic address: aziliz.dreszer@etudiant.univ-reims.fr. Hauptthemen laut MEDLINE: Brachytherapy, Tongue Neoplasms, Carcinoma, Squamous Cell. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
PURPOSE: The study aim was to evaluate efficacy and safety of brachytherapy for the treatment of early-stage tongue carcinoma and identify factors associated with the risk of local recurrence. The interest is to discuss the contribution of brachytherapy among therapeutics of tongue tumors treatments. PATIENTS AND METHODS: Between January 2010 and December 2020, 55 patients with T1T2N0 tongue primitive squamous cell carcinomas were treated with interstitial low-dose-rate, pulsed-dose-rate, or high-dose-rate brachytherapy, with or without neck dissection, at the Centre Oscar Lambret of Lille. The primary objective was to evaluate the efficacy of brachytherapy in terms of local recurrence-free survival (LRFS). The secondary objectives were to estimate regional recurrence-free survival (RRFS), overall survival (OS), and to describe toxicities of brachytherapy. RESULTS: Local recurrence-free survival (LRFS) rates at 1-year, 3-years, and 5-years follow-up were 90.9 %, 62.9 %, and 49.4 %, respectively. The cumulative incidences of local recurrence at 1-year, 3-years, and 5-years follow-up were 1.8 %, 10.2 %, and 12.3 %, respectively; Overall survival (OS) rates at 1-year, 3-years, and 5-years follow-up were 90.9 %, 71.2 %, and 53.4 %, respectively, with a 95 % confidence interval (CI). We identified 14 (25.5 %) grade 3 complications and 10 (29.1 %) grade 2 complications. Age at diagnosis (p < 0.001), smoking (p = 0.018), and tumor stage (p = 0.009) were found to be significant prognostic factors (p < 0.05) for LRFS. CONCLUSION: Brachytherapy is a moderate effective treatment option for early-stage tongue carcinoma. Despite the frequent toxicities generated this approach offers several notable advantages, including preservation of oral anatomy and functions, ultimately leading to an improved quality of life for patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Univ. Lille, CHU Lille, Department of Odontology, Lille, France. Electronic address: aziliz.dreszer@etudiant.univ-reims.fr.
- Univ. Lille, CHU Lille, Department of Odontology, Lille, France.
- Department of Biostatistic, Oscar Lambret Center, Lille, France.
- Department of Radiation oncology and Brachytherapy, Oscar Lambret Center, Lille, France.
Zitieren
APA
Dreszer, A., Olejnik, C., Aymes, E., Barthoulot, M., Liem, X., & Cordoba, A. (2025). Brachytherapy efficacy and safety in the treatment of primitive tongue carcinomas: experience from the Oscar Lambret Center. Journal of Stomatology Oral and Maxillofacial Surgery. https://doi.org/10.1016/j.jormas.2025.102416
Vancouver
Dreszer A, Olejnik C, Aymes E, Barthoulot M, Liem X, Cordoba A. Brachytherapy efficacy and safety in the treatment of primitive tongue carcinomas: experience from the Oscar Lambret Center. Journal of Stomatology Oral and Maxillofacial Surgery. 2025. doi:10.1016/j.jormas.2025.102416
BibTeX
@article{Dreszer2025,
author = {Dreszer, Aziliz and Olejnik, Cécile and Aymes, Estelle and Barthoulot, Maël and Liem, Xavier and Cordoba, Abel},
title = {Brachytherapy efficacy and safety in the treatment of primitive tongue carcinomas: experience from the Oscar Lambret Center},
journal = {Journal of Stomatology Oral and Maxillofacial Surgery},
year = {2025},
doi = {10.1016/j.jormas.2025.102416}
}
EUVIMED